| To: The Ox who wrote (92) | 8/23/2009 6:29:04 PM | | From: footprintsinthesand | | | | | I have been in AGEN since 2004 at 11.60. I have been in and out since then, but after over 5 years of frustation and beating myself up, I've decided to go all in. The latest news is what I have expected of this stock since 2004. Peoples lives are at stake here. Helping sick people, without hope, and making money at the same time is not bad. |
| | Agenus (AGEN) | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: footprintsinthesand who wrote (93) | 8/23/2009 7:25:10 PM | | From: The Dodgy Ticker | | | | | As you can see from my older posts, I was also into AGEN until their RCC results caused the bottom to fall out of their pps. I'm still unclear whether there's anything to their science, but I think that if DNDN has anything of value with THEIR approach, then AGEN should also have value. I havnen't gotten back in yet as you have, but I'm looking at it. Hope you make a million! |
| | Agenus (AGEN) | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: footprintsinthesand who wrote (95) | 12/16/2013 10:24:19 AM | | From: Kirk © | | | | Good Phase 2 results.
AGEN Agenus Positive Phase 3 Brain Cancer Vaccine
From Business Wire press release:
LEXINGTON, Mass.--(BUSINESS WIRE)-- Agenus Inc. 2 hours ago
Agenus Inc. ( AGEN), a biotechnology company developing novel immune system activating treatments for cancers and infectious diseases, today announced results published from a Phase 2 study demonstrated that more than 90% of the patients treated with Prophage Series G-200 were alive at six months after surgery and 30% were alive at twelve months. Additionally, the median overall survival was approximately eleven months. This compares favorably to the expected median survival for recurrent Glioblastoma multiforme (GBM) patients of three to nine months1-7. The primary objective of this multi-center, single arm Phase 2 trial was to assess the survival rate at six months.
The data was published in a manuscript in Neuro-Oncology, the official journal of the Society of Neuro-Oncology. GBM is the most common and most aggressive form of primary brain cancer. Despite approved therapy patients with GBM face a poor prognosis. Prophage Series vaccines are currently being studied in both newly diagnosed and recurrent GBM.
|
| | Agenus (AGEN) | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| To: footprintsinthesand who wrote (95) | 12/16/2013 10:25:01 AM | | From: Kirk © | | | | Good Phase 2 results.
Agenus Announces Positive Phase 2 Brain Cancer Vaccine
From Business Wire press release:
LEXINGTON, Mass.--(BUSINESS WIRE)-- Agenus Inc. 2 hours ago
Agenus Inc. ( AGEN), a biotechnology company developing novel immune system activating treatments for cancers and infectious diseases, today announced results published from a Phase 2 study demonstrated that more than 90% of the patients treated with Prophage Series G-200 were alive at six months after surgery and 30% were alive at twelve months. Additionally, the median overall survival was approximately eleven months. This compares favorably to the expected median survival for recurrent Glioblastoma multiforme (GBM) patients of three to nine months1-7. The primary objective of this multi-center, single arm Phase 2 trial was to assess the survival rate at six months.
The data was published in a manuscript in Neuro-Oncology, the official journal of the Society of Neuro-Oncology. GBM is the most common and most aggressive form of primary brain cancer. Despite approved therapy patients with GBM face a poor prognosis. Prophage Series vaccines are currently being studied in both newly diagnosed and recurrent GBM.
|
| | Agenus (AGEN) | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: StockDung | 2/18/2014 8:56:29 PM | | | | | | May 2005, Gordon participated in a scheme at Joseph Stevens & Co. to artificially raise, maintain,
and manipulate the prices of certain stocks and to induce customers to buy and sell those stocks in
order to receive illegally inflated profits which were shared between principals and registered
representatives. The scheme involved the securities of various companies, including Cypress
Bioscience, Inc. and Antigenics, Inc. The grand larceny count to which Gordon pleaded guilty
alleged that between March 2001 and May 2005, Gordon stole more than three thousand dollars
from an individual.
=====================================================================
UNITED STATES OF AMERICA
Before the
SECURITIES AND EXCHANGE COMMISSION
SECURITIES EXCHANGE ACT OF 1934
Release No. 71561 / February 18, 2014
ADMINISTRATIVE PROCEEDING
File No. 3-15753
In the Matter of
MICHAEL GORDON,
Respondent.
ORDER INSTITUTING
ADMINISTRATIVE PROCEEDINGS
PURSUANT TO SECTION 15(b) OF THE
SECURITIES EXCHANGE ACT OF 1934
AND NOTICE OF HEARING
I.
The Securities and Exchange Commission (“Commission”) deems it appropriate and in the
public interest that public administrative proceedings be, and hereby are, instituted pursuant to
Section 15(b) of the Securities Exchange Act of 1934 (“Exchange Act”) against Michael Gordon
(“Respondent” or “Gordon”).
II.
After an investigation, the Division of Enforcement alleges that:
A. RESPONDENT
1. From October 2000 to February 2007, Gordon was a registered
representative associated with Joseph Stevens & Co., Inc., which, at the time of his association, was
a broker-dealer registered with the Commission. Joseph Stevens & Co. ceased to be registered with
the Commission as of August 2008. Gordon, age 40, is a resident of New Jersey.
B. RESPONDENT’S CRIMINAL CONVICTION
1. On April 21, 2009, before the New York Supreme Court in People v.
Michael Gordon, Case No. 1784-2009, Gordon pleaded guilty to one felony count of attempted
enterprise corruption in violation of New York Penal Law § 110-460.20 and one count of grand
larceny in the third degree in violation of New York Penal Law § 155.35. On May 4, 2012, Gordon
2
was sentenced in that proceeding to five years of probation and ordered to pay $46,799 in
restitution.
2. The attempted enterprise corruption count to which Gordon pleaded arose
out of the conduct of a broker-dealer and alleged, among other things, that between March 2001 and
May 2005, Gordon participated in a scheme at Joseph Stevens & Co. to artificially raise, maintain,
and manipulate the prices of certain stocks and to induce customers to buy and sell those stocks in
order to receive illegally inflated profits which were shared between principals and registered
representatives. The scheme involved the securities of various companies, including Cypress
Bioscience, Inc. and Antigenics, Inc. The grand larceny count to which Gordon pleaded guilty
alleged that between March 2001 and May 2005, Gordon stole more than three thousand dollars
from an individual.
III.
In view of the allegations made by the Division of Enforcement, the Commission deems it
necessary and appropriate in the public interest that public administrative proceedings be instituted
to determine:
A. Whether the allegations set forth in Section II hereof are true and, in connection
therewith, to afford Respondent an opportunity to establish any defenses to such allegations; and
B. What, if any, remedial action is appropriate in the public interest against
Respondent pursuant to Section 15(b)(6) of the Exchange Act.
IV.
IT IS ORDERED that a public hearing for the purpose of taking evidence on the questions
set forth in Section III hereof shall be convened at a time and place to be fixed, and before an
Administrative Law Judge to be designated by further order as provided by Rule 110 of the
Commission’s Rules of Practice, 17 C.F.R. § 201.110.
IT IS FURTHER ORDERED that Respondent shall file an Answer to the allegations
contained in this Order within twenty (20) days after service of this Order, as provided by Rule 220
of the Commission’s Rules of Practice, 17 C.F.R. § 201.220.
If Respondent fails to file the directed answer, or fails to appear at a hearing after being
duly notified, the Respondent may be deemed in default and the proceedings may be determined
against him upon consideration of this Order, the allegations of which may be deemed to be true as
provided by Rules 155(a), 220(f), 221(f), and 310 of the Commission’s Rules of Practice,
17 C.F.R. §§ 201.155(a), 201.220(f), 201.221(f), and 201.310.
This Order shall be served forthwith upon Respondent personally or by certified mail.
3 |
| | Agenus (AGEN) | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (3) |
|
| To: StockDung who wrote (98) | 12/19/2014 11:12:48 AM | | From: Kirk © | | | | Nice news yesterday for AGEN
Positive Outcome of Phase 3 Study of GSK Shingles Vaccine Containing Agenus Adjuvant
GlobeNewswire (Thu 7:00AM EST)
7:06 am Agenus announced that its partner GlaxoSmithKline ( GSK) reported that the ZOE-50 Phase 3 study met its primary endpoint ( AGEN) :
- Analysis of the primary endpoint showed that HZ/su reduced the risk of shingles by 97.2 per cent in adults aged 50 years and older compared to placebo.
- The study, which started in August 2010, is a randomized, placebo-controlled, multicenter, international study involving 16,136 adults aged 50 and older.
- An additional GSK trial to evaluate the ability of HZ/su to prevent shingles is underway in adults aged 70 and older.
 |
| | Agenus (AGEN) | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| |
